We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-4.24%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$733M
AUM Growth
+$21.5M
Cap. Flow
+$93.1M
Cap. Flow %
12.7%
Top 10 Hldgs %
32.84%
Holding
138
New
34
Increased
32
Reduced
32
Closed
20

Top Buys

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$25.7M
2
SKYE icon
Skye Bioscience
SKYE
+$15.4M
3
ASML icon
ASML
ASML
+$9.52M
4
CRM icon
Salesforce
CRM
+$8.99M
5
BBIO icon
BridgeBio Pharma
BBIO
+$8.86M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$16.9M
2
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$9.57M
3
CAMT icon
Camtek
CAMT
+$6.97M
4
CATX icon
Perspective Therapeutics
CATX
+$6.61M
5
NVMI
Nova
NVMI
+$6.23M

Sector Composition

Rank Sector Weight
1 Healthcare 59.43%
2 Technology 17.13%
3 Communication Services 3.05%
4 Consumer Discretionary 3%
5 Utilities 0.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASML icon
26
ASML
ASML
$626B
$10.1M 1.38%
+9,901
New +$9.52M
MRUS
27
DELISTED
Merus
MRUS
$8.74M 1.19%
147,633
-1,700
-1% -$82.3K
CRM icon
28
Salesforce
CRM
$151B
$8.64M 1.18%
+33,600
New +$8.99M
IMTX icon
29
Immatics
IMTX
$1.18B
$8.5M 1.16%
731,111
+65,000
+10% +$732K
CATX icon
30
Perspective Therapeutics
CATX
$332M
$7.85M 1.07%
786,909
-457,453
-37% -$6.61M
PHVS icon
31
Pharvaris
PHVS
$2.28B
$7.58M 1.03%
403,265
+10,388
+3% +$211K
MRK icon
32
Merck
MRK
$322B
$7.38M 1.01%
59,600
-44,000
-42% -$5.67M
RZLT icon
33
Rezolute
RZLT
$454M
$7.34M 1%
1,707,999
+711,289
+71% +$2.44M
HELP
34
Cybin Inc
HELP
$485M
$6.93M 0.95%
673,195
– –
VIGL
35
DELISTED
Vigil Neuroscience
VIGL
$6.77M 0.92%
1,692,166
-38,248
-2% -$131K
IONS icon
36
Ionis Pharmaceuticals
IONS
$8.6B
$6.68M 0.91%
+140,238
New +$5.75M
INZY
37
DELISTED
Inozyme Pharma
INZY
$6.52M 0.89%
1,462,724
+89,817
+7% +$435K
ABBV icon
38
AbbVie
ABBV
$443B
$6.52M 0.89%
38,000
– –
PANW icon
39
Palo Alto Networks
PANW
$270B
$6.1M 0.83%
+36,000
New +$5.38M
S icon
40
SentinelOne
S
$6.53B
$5.97M 0.81%
283,804
-267,014
-48% -$5.48M
TSEM icon
41
Tower Semiconductor
TSEM
$24.8B
$5.88M 0.8%
149,600
-30,000
-17% -$1.07M
AMAT icon
42
Applied Materials
AMAT
$403B
$5.81M 0.79%
24,604
-7,396
-23% -$1.59M
ENPH icon
43
Enphase Energy
ENPH
$4.96B
$5.66M 0.77%
56,792
+9,609
+20% +$1.12M
NICE icon
44
CALL
Nice
NICE
$5.79B
$5.52M 0.75%
+32,100
New +$6.6M
NVS icon
45
Novartis
NVS
$297B
$5.32M 0.73%
50,000
– –
ACAD icon
46
Acadia Pharmaceuticals
ACAD
$4.43B
$5.32M 0.73%
327,539
+202,539
+162% +$3.27M
BBIO icon
47
CALL
BridgeBio Pharma
BBIO
$15.7B
$5.18M 0.71%
204,600
+154,600
+309% +$4.23M
MLYS icon
48
Mineralys Therapeutics
MLYS
$2.25B
$5.18M 0.71%
442,752
-216,051
-33% -$2.72M
FDMT icon
49
4D Molecular Therapeutics
FDMT
$532M
$5.09M 0.69%
242,526
+80,365
+50% +$2.02M
MU icon
50
Micron Technology
MU
$930B
$4.87M 0.66%
+37,000
New +$4.66M
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2024 Portfolio in Review

As of Q2 2024, Sphera Funds Management held 138 positions worth $733M, up 3% from $712M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Sphera Funds Management deployed $93.1M of net new capital in Q2 2024, opening 34 new positions and adding to 32 existing holdings. Its largest new stake was Skye Bioscience: 1,298,312 shares worth $10.4M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 65% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $16.9M trimmed.

  • Sphera Funds Management's largest Q2 2024 buy was Skye Bioscience: 1,298,312 shares worth $10.4M.
  • Sphera Funds Management added most to Broadcom in Q2 2024, an estimated $25.7M increase.
  • Sphera Funds Management's biggest Q2 2024 reduction was Teva Pharmaceuticals, cutting an estimated $16.9M.
  • Sphera Funds Management fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $9.57M.
  • Sphera Funds Management's ten largest holdings make up 33% of its $733M portfolio in Q2 2024.
  • Sphera Funds Management opened 34 new positions and closed 20 in Q2 2024.
  • Sphera Funds Management's portfolio value rose 3% quarter-over-quarter to $733M.

Based on Sphera Funds Management's 13F filing for Q2 2024, filed 14 Aug 2024.